Sales fall at J&J Vision Care

Johnson & Johnson reported a decrease in its Vision Care segment's worldwide sales for the second quarter of 2009 to $630m in comparison to $639m for the same period in 2008. The unaudited results were affected by a negative currency effect of 3.3 per cent.

Overall sales for the company for the second quarter were $15.2bn, a decrease of 7.4 per cent in comparison to the same period in 2008. J&J's overall European results for the quarter fell to $3.972bn from $4.547bn the previous year.

William C Weldon, the company's chairman and chief executive officer, said he was proud of what he called 'very solid operational results in light of the significant impacts of patent expirations and the economic environment'.